Postcardiotomy extracorporeal membrane oxygenator: No longer a bridge to no where?
cardiogenic shock
extracorporeal membrane oxygenator
perfusion
postcardiotomy shock
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
29
7
2020
medline:
15
5
2021
entrez:
29
7
2020
Statut:
ppublish
Résumé
Postcardiotomy extracorporeal membrane oxygenation (PC-ECMO) represents a unique subset of critically ill patients, with a paucity of data regarding long-term survival and correlated characteristics. We present a retrospective cohort of PC-ECMO patients, with outcomes at 1 and 3 years. Data were collected retrospectively for all patients requiring ECMO within 72 hours of an index cardiac operation (excluding assist devices and transplants). Primary outcomes were the ability to wean from ECMO, hospital survival, and long-term survival. Thirty-one patients required PC-ECMO, representing a total of 172 days of ECMO support. Overall survival data were the ability to wean 58%, hospital survival 52%, 1-month survival 42%. The estimated 12- and 36-month survival for all PC-ECMO patients was 35% and 29%, respectively. Twelve and 36-month survival for all hospital survivors was 62% and 56%. Operative times, the Society of Thoracic Surgeons risk scores, type of operation, open chest status, hemorrhage, and cannulation location, and timing were all compared. Centrally cannulated patients were more likely to wean from ECMO (83% vs 44%; P = .03), and survive hospitalization (75% vs 36%; P = .04) and trended toward long-term survival benefit (67% vs 33%; P = .06). Otherwise, no statistically significant relationships were observed. Central cannulation may provide benefits in the postcardiotomy patient, compared to peripheral strategies. Twelve and 36-month survival for all PC-ECMO patients was 35% and 29%. For hospital survivors, 12 and 36-month survival 62% 56% at 36. These data support PC-ECMO as a reasonable salvage strategy, with midterm survival comparable to other surgically treated diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Postcardiotomy extracorporeal membrane oxygenation (PC-ECMO) represents a unique subset of critically ill patients, with a paucity of data regarding long-term survival and correlated characteristics. We present a retrospective cohort of PC-ECMO patients, with outcomes at 1 and 3 years.
METHODS
METHODS
Data were collected retrospectively for all patients requiring ECMO within 72 hours of an index cardiac operation (excluding assist devices and transplants). Primary outcomes were the ability to wean from ECMO, hospital survival, and long-term survival.
RESULTS
RESULTS
Thirty-one patients required PC-ECMO, representing a total of 172 days of ECMO support. Overall survival data were the ability to wean 58%, hospital survival 52%, 1-month survival 42%. The estimated 12- and 36-month survival for all PC-ECMO patients was 35% and 29%, respectively. Twelve and 36-month survival for all hospital survivors was 62% and 56%. Operative times, the Society of Thoracic Surgeons risk scores, type of operation, open chest status, hemorrhage, and cannulation location, and timing were all compared. Centrally cannulated patients were more likely to wean from ECMO (83% vs 44%; P = .03), and survive hospitalization (75% vs 36%; P = .04) and trended toward long-term survival benefit (67% vs 33%; P = .06). Otherwise, no statistically significant relationships were observed.
CONCLUSIONS
CONCLUSIONS
Central cannulation may provide benefits in the postcardiotomy patient, compared to peripheral strategies. Twelve and 36-month survival for all PC-ECMO patients was 35% and 29%. For hospital survivors, 12 and 36-month survival 62% 56% at 36. These data support PC-ECMO as a reasonable salvage strategy, with midterm survival comparable to other surgically treated diseases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2208-2215Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Extracorporeal Life Support Organization-ECMO and ECLS. (2019, July 25). ECLS Registry Report International Summary. https://www.elso.org/Registry/Statistics/InternationalSummary.aspx. Accessed on September 27, 2019
Smith C, Bellomo R, Raman JS, et al. An extracorporeal membrane oxygenation-based approach to cardiogenic shock in an older population. Ann Thorac Surg. 2001;71(5):1421-1427. https://doi.org/10.1016/s0003-4975(00)02504-2
Doll N, Kiaii B, Borger M, et al. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg. 2004;77(1):151-157. https://doi.org/10.1016/s0003-4975(03)01329-8
Doll N, Fabricius A, Borger MA, et al. Temporary extracorporeal membrane oxygenation in patients with refractory postoperative cardiogenic shock: a single venter experience. J Card Surg. 2003;18(6):512-518. https://doi.org/10.1046/j.0886-0440.2003.02061.x
Raffa GM, Gelsomino S, Sluijpers N, et al. In-hospital outcome of post-cardiotomy extracorporeal life support in adult patients: the 2007-2017 Maastricht experience. Crit Care Resusc. 2017;19(Suppl 1):53-61.
Guihaire J, Van SD, Rouze S, et al. Clinical outcomes in patients after extracorporeal membrane oxygenation support for post-cardiotomy cardiogenic shock: a single-centre experience of 92 cases. Interact Cardiovasc Thorac Surg. 2017;25(3):363-369. https://doi.org/10.1093/icvts/ivx155
Patel S, Lipinski J, Al-Kindi S, et al. Simultaneous venoarterial extracorporeal membrane oxygenation impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J. 2019;65(1):21-28. https://doi.org/10.1097/MAT.0000000000000767
Moazami N, Pasque MK, Moon MR, et al. Mechanical support for isolated right ventricular failure in patients after cardiotomy. J Heart Lung Transplant. 2004;23(12):1371-1375.
Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int. 2014;85(1):158-165.
Nordio M, Limido A, Maggiore U, et al. Survival in patients treated by long-term dialysis compared with the general population. Am J Kidney Dis. 2012;59(6):819-828.
American Cancer Society. Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/. Accessed January 12, 2020.
National Comprehensive Cancer Network. (2019). Pancreatic Adenocarcinoma (version 3.2019). https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed January 12, 2020.